Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging

The advent of Adcetris™ and Kadcyla™, two recently FDA-approved antibody–drug conjugates (ADCs), in the clinic has had a major impact on the treatment of lymphoma and breast cancer patients, respectively, worldwide. Despite these successes many new ADCs fail at various stages of development, often d...

Descripción completa

Detalles Bibliográficos
Autores principales: Schumacher, Felix F., Nunes, João P. M., Maruani, Antoine, Chudasama, Vijay, Smith, Mark E. B., Chester, Kerry A., Baker, James R., Caddick, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2014
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159697/
https://www.ncbi.nlm.nih.gov/pubmed/25103319
http://dx.doi.org/10.1039/c4ob01550a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159697/
https://www.ncbi.nlm.nih.gov/pubmed/25103319
http://dx.doi.org/10.1039/c4ob01550a

Ejemplares similares